Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 3/2012

01-06-2012 | Review Article

Review of services provided by pharmacies that promote healthy living

Authors: David Brown, Jane Portlock, Paul Rutter

Published in: International Journal of Clinical Pharmacy | Issue 3/2012

Login to get access

Abstract

Background The recognition that community pharmacies have the potential to make a greater contribution to promoting public health has led to a new concept, called the Healthy Living Pharmacy (HLP). These are designed to meet public health needs through a tiered commissioning framework delivering health and well being services through community pharmacy, tailored to local requirements for tackling health inequalities. Aim To search the literature for quality evidence to support the inclusion of services in the HLP portfolio and suggest areas where more evidence is required. Method A systematic review of the research literature covering the period January 1990–August 2011 inclusive, using MEDLINE, EMBASE, Pharmline, NHS Evidence and the Cochrane databases. On-line searching of the grey literature (e.g. conference proceedings) was also carried out. Standard methods of assessing quality were employed. Results A total of 377 papers were included. Over time, there was a marked increase in frequency of publications reflecting a growing pharmacy interest in the public healthcare agenda; over a third (35 %) of papers appeared in the last three-year study period. The body of research had a wide geographical basis; contributions were as follows: UK (51.5 %), US (20.4 %), Australia/New Zealand (9.8 %), Europe (7.7 %) and Canada (7.2 %). The topics of contraception, cardiovascular disease prevention, diabetes and smoking cessation accounted for 40 % of included papers. The literature supports the introduction of specific community pharmacy services, targeted at customer groups, both with and without pre-existing diseases. Good evidence exists for smoking cessation, cardiovascular disease prevention, hypertension and diabetes. Some good evidence exists for interventions on asthma and heart failure. The evidence supporting weight management, sexual health, osteoporosis detection, substance abuse and chronic obstructive pulmonary disease is weak and needs development. Conclusion There is strong evidence for the role of community pharmacy in a range of services, not only aimed at improving general health, but also maintaining the health of those with existing disease. In other areas, the evidence is less strong and further research is required to justify their inclusion in a HLP portfolio.
Literature
1.
2.
3.
4.
5.
6.
7.
Blenkinsopp A, Anderson C, Armstrong M. The contribution of community pharmacy to improving the public’s health. Report 2: evidence from the UK non peer-reviewed literature 1990–2002, 2003. Available at http://​eprints.​nottingham.​ac.​uk/​1572/​. Accessed 30 Jan 2012.
8.
9.
10.
11.
12.
13.
Maguire TA, McElnay JC, Drummond A. A randomised controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001;96:325–31.PubMedCrossRef
14.
Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches linking hospital to the community. J Pharm Pract Res. 2002;32(1):57–62.
15.
Dent LA, Harris KJ, Noonan CW. Randomised trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. Ann Pharmacother. 2009;43(2):194–210.PubMed
16.
Crealey G, McElnay JC, Maguire TA. Costs and effects associated with a community pharmacy based smoking cessation programme. Pharmacoeconomics. 1998;12:323–33.CrossRef
17.
Sinclair H, Silcock J, Bond CM, Lennox S, Winfield AJ. The cost-effectiveness of intensive pharmaceutical intervention in assisting people to stop smoking. Int J Pharm Pract. 1999;7:107–12.CrossRef
18.
Sinclair HK, Bond CM, Lennox AS, Silcock J, Winfield AJ, Donnan PT. Training pharmacists and pharmacy assistants in the stage of change model of smoking cessation: a randomised controlled trial in Scotland. Tobacco Control. 1998;7:253–61.PubMedCrossRef
19.
20.
Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008;42(9):1195–207.PubMedCrossRef
21.
Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Pub Health Med. 2003;25(2):144–53.CrossRef
22.
Nola KM, Gourley DR, Portner TS, Gourley K, Solomon DK, Elam M, Regel B. (2000) Clinical and humanistic outcomes of a lipid management programme in the community pharmacy setting. J Am Pharm Assoc. 2000;40:166–73.
23.
Simpson SA, Johnson JA, Tsuyuki RT. Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy. 2001;21(5):627–35.PubMedCrossRef
24.
Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS. A randomised trial of the effect of community pharmacy intervention on cholesterol risk: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162(10):1149–55.PubMedCrossRef
25.
26.
Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81.PubMedCrossRef
27.
Carter BL, Rogers M, Daly J, Zheng S, James P. The potency of team-based care interventions in hypertension. Arch Int Med. 2009;169(19):1748–55.CrossRef
28.
Carter BL, Ardery G, Dawson J, James PA, Bergus G, Doucette WR, Chrischilles EA, Franciscus CL. Physician and pharmacists collaboration in improved blood pressure control. Arch Intern Med. 2009;169(21):1996–2002.PubMedCrossRef
29.
Jones C, Simpson SH, Mitchell D, Haggerty S, Campbell N, Then K. Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP). Can J Cardiol. 2008;24(7):561–7.PubMedCrossRef
30.
Botomino A, Bruppacher R, Krahenbuehl S, Hersberger KE. Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies. Pharm World Sci. 2007;30:222–6.PubMedCrossRef
31.
Blenkinsopp A, Anderson C, Armstrong M. Community pharmacy’s contribution to improving the public’s health: the case of weight management. Int J Pharm Pract. 2008;16:123–5.CrossRef
32.
Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41:1569–82.PubMedCrossRef
33.
Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421–36.PubMedCrossRef
34.
Fornos JA, Andres NF, Andres JC, Guerra MM, Egea B. A pharmacotherapy follow-up programme in patients with Type-2 diabetes in community pharmacies in Spain. Pharm World Sci. 2006;28(2):65–72.PubMedCrossRef
35.
Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J, Oritz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008;65(19):1841–5.PubMedCrossRef
36.
Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, Lau P, Peterson G, Stewart K, Taylor S, Wilkinson J. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24:677–83.PubMedCrossRef
37.
McLean DL, McAllister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, Tsuyuki RT. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus. Arch Int Med. 2008;168(21):2355–61.CrossRef
38.
Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of hypertension medication therapy management programmes in patients with diabetes. J Am Pharm Assoc. 2009;49(2):164–70.CrossRef
39.
40.
Benavides S, Rodriguez JC, Manuscalco-Feichtl M. Pharmacist involvement in improving asthma outcomes in various healthcare settings: 1997 to present. Ann Pharmacother. 2009;43(1):85–97.PubMedCrossRef
41.
Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, Brusselle G. Effectiveness of pharmacist intervention for asthma control improvement. Eur Resp J. 2008;31(4):790–9.CrossRef
42.
Bereznicki BJ, Peterson GM, Jackson SL, Walters H, Fitzmaurice K, Gee P. Pharmacist-initiated general practitioner referral of patients with suboptimal asthma management. Pharm World Sci. 2008;30(6):869–75.PubMedCrossRef
43.
Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic and economic outcomes of a community-based medication therapy management program for asthma. J Am Pharm Assoc. 2006;46(2):133–47.CrossRef
44.
Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study. J Asthma. 2007;44(1):57–64.PubMedCrossRef
45.
Saini B, Filipovska F, Bosnic-Anticevich S, Taylo S, Krass I, Armour C. An evaluation of a community pharmacy-based rural asthma management service. Aust J Rural Health. 2008;16(2):100–8.PubMedCrossRef
46.
Basheti IA, Armour CL, Bosnich-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Educ Couns. 2008;72(1):26–33.PubMedCrossRef
47.
Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure. Arch Intern Med. 2008;168(7):687–94.PubMedCrossRef
48.
Castillo D, Guayta R, Giner J, Burgos F, Capdevila C, Soranio JB. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study. Resp Med. 2009;103:839–45.CrossRef
49.
Efthymiou N, Crampton R. Establishing an anticoagulation service in community pharmacy. Pharmacy Management. 2007;23(4):10–5.
50.
Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc. 2006;46(2):168–82.CrossRef
51.
Marrero W, Hernandez L, Garcia R, Gutierrez LM. A programme of immunisation against influenza in adults aged 65 years or older in one community pharmacy in Puerto Rica. Puerto Rico Health Sci J. 2006;25(1):35–42.
52.
Fuchs J. The provision of pharmaceutical advice improves patient vaccination status. Pharm Pract. 2006;4(4):163–7.
53.
Noble K, Holden M, Warner GA. solution to improving uptake of hepatitis B immunisation in at risk groups, through collaboration and adopting an integrated approach with pharmacists as service providers. Int J Pharm Pract. 2010;18(2):43.
54.
Landau SC, Tapias MP, McGhee BT. Birth control within each: a national survey of women’s attitudes to, and interest in pharmacy access to hormonal contraception. Contraception. 2006;74(6):463–70.PubMedCrossRef
55.
McAllister KF, Elliott L, Thomson DA, Bigrigg A, Mackie CM. Evaluation of a young person’s sexual health service in a commercial setting. J Fam Plann Reprod Health Care. 2002;28(4):203–6.PubMedCrossRef
56.
Mackie CM, Elliott L, Bigrigg A, McAllister KF. Public and private collaboration in establishing a young person’s sexual health clinic in a commercial setting. J Fam Plann Reprod Health Care. 2002;28(4):201–3.PubMedCrossRef
57.
Van Bergen J, Postma M, Peerbooms P, Spangenberg A, Tjen-ATak J, Bindels P. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatisin a high-risk health centre population in Amsterdam using mailed home-collected urine samples. Int J STD AIDS. 2004;15:791–802.
58.
Baraitser P, Pearce V, Holmes J, Horne N, Boynton PM. Chlamydia testing in community pharmacies: evaluation of a feasibility pilot in south east London. Qual Saf Health Care. 2007;16:303–7.PubMedCrossRef
59.
Dabrera G, Pinson D, Whiteman S. Chlamydia screening by community pharmacists: a qualitative study. J Fam Plan Reprod Health Care. 2011;37(1):17–21.CrossRef
60.
Brabin L, Thomas G, Hopkins M, O’Brien K, Roberts SA. Delivery of Chlamydia screening to young women requesting emergency hormonal contraception at pharmacies in Manchester, UK: a prospective study. BMC Women’s Health. 2009;9:7.PubMedCrossRef
61.
62.
Anderson C, Blenkinsopp A. Community pharmacy supply of emergency hormonal contraception: a structured literature review of international evidence. Hum Reprod. 2006;21(1):272–84.PubMedCrossRef
63.
Raine TR, Harper CC, Rocca CH, Fischer R, Padian N, Klausner JD, Darney PD. Direct access to emergency contraception through pharmacies and effect on unintended pregnancies and STIs: a randomised controlled trial. JAMA. 2005;293:54–62.PubMedCrossRef
64.
Marston C, Meltzer M, Majeed A. Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys. BMJ. 2005;331:271.PubMedCrossRef
65.
Britton R, Scott J. Community pharmacy services to drug misusers in the south west of England: results of the 2003–2004 postal survey. Int J Pharm Pract. 2006;14:235–41.CrossRef
66.
Matheson C, Bond CM, Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health. 2007;29(4):350–7.CrossRef
67.
Lawrie T, Matheson C, Bond CM, Roberts K. Pharmacy customers’ views and experiences of using pharmacies which provide drug misuse services. Drug Alcohol Rev. 2004;23(2):195–202.PubMedCrossRef
68.
Sheridan J, Manning V, Ridge G, Mayet S, Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction. 2007;102(11):1824–30.PubMedCrossRef
69.
Jaffray M, Matheson C, Bond CM, Lee AJ, McLernon DJ, Johnstone A, Davidson B, Skea L. A cluster randomised trial of enhanced pharmacy services (EPS) to improve outcomes for patients on methadone maintenance therapy. Int J Pharm Pract. 2011;19(S1):4.
70.
Cameron J, Gilchrist G, Roberts K. Needle exchange services: a profile of service users in community pharmacies and other settings. Int J Pharm Pract. 2004;12:211–5.CrossRef
71.
Watson MC, Inch M, Jaffray M, Stewart D. Screening and brief intervention for alcohol misuse delivered in a community pharmacy setting: a pilot study. Int J Pharm Pract. 2011;19(1):5.CrossRef
72.
Watson MC, Blenkinsopp A. The feasibility of providing community pharmacy-based services for alcohol misuse: a literature review. Int J Pharm Pract. 2009;17(4):199–205.PubMedCrossRef
73.
McCaig D, Fitzgerald N, Stewart D. Provision of advice on alcohol use in community pharmacy: a cross-sectional survey of pharmacists’ practice, knowledge, views and confidence. Int J Pharm Pract. 2010;19:171–8.CrossRef
74.
Horsfield E, Sheridan J, Anderson C. What do community pharmacists think about undertaking screening and brief interventions with problem drinkers? Results of a qualitative study in New Zealand and England. Int J Pharm Pract. 2010;19:192–200.CrossRef
75.
Sheridan J, Wheeler A, Chen L. Screening and brief interventions for alcohol: attitudes, knowledge and experience of community pharmacists in Auckland. N Z Drug Alcohol Rev. 2008;27(4):380–7.CrossRef
76.
Fitzgerald N, McCaig DJ, Watson H, Thomson D, Stewart DC. Development, implementation and evaluation of a pilot project to deliver interventions on alcohol issues in community pharmacies. Int J Pharm Pract. 2008;16(1):17–22.CrossRef
77.
Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc. 2004;44(2):161–7.CrossRef
78.
Lata PF, Binkley NC, Elliott ME. Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. Menopause. 2002;9(6):449–55.PubMedCrossRef
79.
Elliott ME, Meek PD, Kanous NL, Schill GR, Weinswig PA, Bohlman JP. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. J Am Pharm Assoc. 2002;42(1):101–10.CrossRef
80.
MacLaughlin EJ, MacLaughlin AA, Snella KA, Winston TS, Fike DS, Raehl CR. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy. 2005;25(3):379–86.PubMedCrossRef
81.
Summers KM, Brock TP. Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother. 2005;39:243–8.PubMedCrossRef
82.
Naunton M, Peterson GM, Jones G. Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother. 2006;40(1):38–44.PubMed
83.
Johnson JF, Koenigsfeld C, Hughell L, Parsa RA, Bravard S. Bone health screening, education and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc. 2008;48(3):379–87.CrossRef
84.
Crockett JA, Taylor SJ, McLeod LJ. Patient responses to an integrated service, initiated by community pharmacists, for the prevention of osteoporosis. Int J Pharm Pract. 2008;16(2):65–72.CrossRef
85.
Youssef S. Patients taking warfarin: problems revealed by medicines use reviews. Pharm J. 2008;280:662.
86.
Portlock J, Holden M, Patel S. A community pharmacy asthma MUR project in Hampshire and the Isle of Wight. Pharm J. 2009;282:109–12.
87.
88.
Anonymous. Pharmaceutical needs assessment (PNA). Heart of Birmingham Teaching Primary Care Trust, Birmingham 2010.
89.
90.
Blenkinsopp A, Holmes J, Mitra G, Pringle M. Joining up self-care: evaluation of a PCT-wide programme of support for self-care. Primary Health Care Res Devel. 2009;10:83–97.CrossRef
91.
Hind C, Bond C, Lee A, van Teijlingen E. Travel medicine services from community pharmacy: evaluation of a pilot service. Pharm J. 2008;281:625–8.
92.
Maunder PEV, Landes DP. An evaluation of the role played by community pharmacies in oral healthcare situated in a primary care trust in the north of England. Br Dent J. 2005;199(4):219–23.PubMedCrossRef
93.
Ewan D. Evaluation of mental health care interventions made by three community pharmacists. Int J Pharm Pract. 2001;9:225.CrossRef
94.
Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack W, Grabowsy J. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull. 2009;37(4):727–36.PubMedCrossRef
95.
Aryana M, Coggins N, Hudson S, McKellar S, Grant E, Bryson S, Edwards N. Evaluation of a pharmacy-led community based, health information network to promote cancer prevention. Pharm World Sci. 2009;31(1):46–7.
96.
McGuire TR, Leypoldt M, Narducci WA, Ward K. Accessing rural populations: role of the community pharmacist in a breast and cervical cancer screening programme. J Eval Clin Pract. 2007;13(1):146–9.PubMedCrossRef
97.
Anonymous. Patients invited to walk to health by pharmacists in Norfolk initiative. Pharm J. 2008; 281–410.
98.
Anderson C, Rajyaguru R. The role of community pharmacists and medicines counter assistants in health promotion: reflections from a folic acid campaign. Int J Pharm Pract. 2002;3:17–22.CrossRef
99.
Jong-Van De, den Berg LTW. Monitoring of the folic acid supplementation program in the Netherlands. Food Nutr Bull. 2008;29(2):S210–3.
100.
Meijer WM, de Smit DJ, Jurgens RA, Van den Berg LTW de Jong. Improved preconceptional use of folic acid after patient education in pharmacies: promising results of a pilot study in the Netherlands. Int J Pharm Pract. 2005;13(1):47–52.CrossRef
Metadata
Title
Review of services provided by pharmacies that promote healthy living
Authors
David Brown
Jane Portlock
Paul Rutter
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9634-2

Other articles of this Issue 3/2012

International Journal of Clinical Pharmacy 3/2012 Go to the issue

Research Article

Effects of short-term addition of NSAID to diuretics and/or RAAS-inhibitors on blood pressure and renal function

Case Report

Telbivudine myopathy in a patient with chronic hepatitis B

Case Report

Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report

Research Article

RETRACTED ARTICLE: Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case–control study

Short Research Report

Characteristics of HIV patients referred to a medication adherence program in Switzerland

Review Article

Outpatient parenteral antimicrobial therapy with ceftriaxone, a review

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits